Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

TERMINATED

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Lead Sponsor:

MedImmune LLC

Conditions:

Lymphoma

Leukemia

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the seconda...

Eligibility Criteria

Inclusion

  • Individuals may be eligible for this study if they are 18 years of age or older and:
  • Have one of the following types of T-Cell Lymphoproliferative disorders such as Cutaneous T-cell Lymphoma (CTCL), Peripheral T-cell Lymphoma (PCTL), Large Cell Lymphoma (LGL), or Adult T-cell Lymphoma (ATL). Patients should have disease that is resistant or refractory to the front-line therapy, except ATL patients for whom there is no standard therapy.
  • At least 30% of tumor cells must be CD2 positive.
  • Karnofsky Performance status of greater than or equal to 70% (able to care for themselves; but unable to carry on normal activity or to do active work).
  • At least 3 weeks must have passed since prior systemic cytotoxic chemotherapy, prolonged or cytolytic steroid therapy or major surgery, and all treatment-related toxicities must have resolved prior to the first MEDI-507 administration (except thrombocytopenia).
  • Have no prior treatment with MEDI-507.

Exclusion

    Key Trial Info

    Start Date :

    February 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    80 Patients enrolled

    Trial Details

    Trial ID

    NCT00105313

    Start Date

    February 1 2005

    Last Update

    June 14 2007

    Active Locations (11)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (11 locations)

    1

    USC/Norris Cancer Center

    Los Angeles, California, United States, 90033

    2

    Yale Cancer Center

    New Haven, Connecticut, United States, 06520

    3

    Georgetown University Medical Center, Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia, United States, 20007

    4

    H. Lee Moffitt Cancer Ctr & Research Institute Div of Hem/Onc

    Tampa, Florida, United States, 33612